Intervention
PG-102
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownAn Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.NCT06891287 · 2025-12-30
RECRUITINGPhase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes MellitusNCT07187856 · 2026-01-01
NOT_YET_RECRUITINGPhase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesNCT06712615 · 2024-12-05
ACTIVE_NOT_RECRUITINGCommon conditions
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
RECRUITING1
Phase mix
PHASE22
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.